LPS activates ADAM9 dependent shedding of ACE from endothelial cells

Biochemical and Biophysical Research Communications

Volumn 421, Issue 1, 2012, Pages 70-75

  English, William R ^a   Corvol, Pierre ^b   Murphy, Gillian ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b INSERM   (France)

Author keywords

ACE; ADAM9; Endothelial; LPS; TNF ; TNFRII

Indexed keywords

ADAM PROTEIN; ADAM9 PROTEIN; BATIMASTAT; COMPLEMENTARY DNA; DIPEPTIDYL CARBOXYPEPTIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BIOTINYLATION; CELL STRAIN HEK293; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; UMBILICAL VEIN;

ADAM PROTEINS; CATALYTIC DOMAIN; CELL MEMBRANE; DISINTEGRINS; DNA, COMPLEMENTARY; ENDOTHELIAL CELLS; HEK293 CELLS; HUMANS; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASES; MEMBRANE PROTEINS; METALLOPROTEASES; NF-KAPPA B; PEPTIDYL-DIPEPTIDASE A; PHENYLALANINE; PHORBOL ESTERS; PROTEASE INHIBITORS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; THIOPHENES; TUMOR NECROSIS FACTOR-ALPHA;

BACTERIA (MICROORGANISMS);

EID: 84860341015     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.03.113     Document Type: Article

References (34)

1. Fuchs S., Frenzel K., Xiao H.D., Adams J.W., Zhao H., Keshelava G., Teng L., Bernstein K.E. Newly recognized physiologic and pathophysiologic actions of the angiotensin-converting enzyme. Curr. Hypertens. Rep. 2004, 6:124-128.
2. Coates D. The angiotensin converting enzyme (ACE). Int. J. Biochem. Cell Biol. 2003, 35:769-773.
3. Igic R., Behnia R. Properties and distribution of angiotensin I converting enzyme. Curr. Pharm. Des. 2003, 9:697-706.
4. Corvol P., Michaud A., Soubrier F., Williams T.A. Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme. J. Hypertens. Suppl. 1995, 13(Suppl 3):S3-10.
5. Beldent V., Michaud A., Bonnefoy C., Chauvet M.T., Corvol P. Cell surface localization of proteolysis of human endothelial angiotensin I-converting enzyme. Effect of the amino-terminal domain in the solubilization process. J. Biol. Chem. 1995, 270:28962-28969.
6. Parvathy S., Oppong S.Y., Karran E.H., Buckle D.R., Turner A.J., Hooper N.M. Angiotensin-converting enzyme secretase is inhibited by zinc metalloprotease inhibitors and requires its substrate to be inserted in a lipid bilayer. Biochem. J. 1997, 327(Pt 1):37-43.
7. Woodman Z.L., Oppong S.Y., Cook S., Hooper N.M., Schwager S.L., Brandt W.F., Ehlers M.R., Sturrock E.D. Shedding of somatic angiotensin-converting enzyme (ACE) is inefficient compared with testis ACE despite cleavage at identical stalk sites. Biochem. J. 2000, 347(Pt 3):711-718.
8. Doan T.N., Gletsu N., Cole J., Bernstein K.E. Genetic manipulation of the renin-angiotensin system. Curr. Opin. Nephrol. Hypertens. 2001, 10:483-491.
9. Kessler S.P., Senanayake Pd P., Scheidemantel T.S., Gomos J.B., Rowe T.M., Sen G.C. Maintenance of normal blood pressure and renal functions are independent effects of angiotensin-converting enzyme. J. Biol. Chem. 2003.
10. Cole J.M., Khokhlova N., Sutliff R.L., Adams J.W., Disher K.M., Zhao H., Capecchi M.R., Corvol P., Bernstein K.E. Mice lacking endothelial ACE: normal blood pressure with elevated angiotensin II. Hypertension 2003, 41:313-321.
11. van Esch J.H., Tom B., Dive V., Batenburg W.W., Georgiadis D., Yiotakis A., van Gool J.M., de Bruijn R.J., de Vries R., Danser A.H. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension 2005, 45:120-125.
12. Votta-Velis E.G., Minshall R.D., Visintine D.J., Castellon M., Balyasnikova I.V. Propofol attenuates endotoxin-induced endothelial cell injury angiotensin-converting enzyme shedding and lung edema. Anesth. Analg. 2007, 105:1363-1370. table of content.
13. Parkin E.T., Trew A., Christie G., Faller A., Mayer R., Turner A.J., Hooper N.M. Structure-activity relationship of hydroxamate-based inhibitors on the secretases that cleave the amyloid precursor protein, angiotensin converting enzyme, CD23, and pro-tumor necrosis factor-alpha. Biochemistry 2002, 41:4972-4981.
14. Sadhukhan R., Santhamma K.R., Reddy P., Peschon J.J., Black R.A., Sen I. Unaltered cleavage and secretion of angiotensin-converting enzyme in tumor necrosis factor-alpha-converting enzyme-deficient mice. J. Biol. Chem. 1999, 274:10511-10516.
15. Parvathy S., Karran E.H., Turner A.J., Hooper N.M. The secretases that cleave angiotensin converting enzyme and the amyloid precursor protein are distinct from tumour necrosis factor-alpha convertase. FEBS Lett. 1998, 431:63-65.
16. Vazeux G., Cotton J., Cuniasse P., Dive V. Potency and selectivity of RXP407 on human, rat, and mouse angiotensin-converting enzyme. Biochem. Pharmacol. 2001, 61:835-841.
17. Knight C.G., Willenbrock F., Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992, 296:263-266.
18. Amour A., Slocombe P.M., Webster A., Butler M., Knight C.G., Smith B.J., Stephens P.E., Shelley C., Hutton M., Knauper V., Docherty A.J., Murphy G. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 1998, 435:39-44.
19. Murray J., Barbara J.A., Dunkley S.A., Lopez A.F., Van Ostade X., Condliffe A.M., Dransfield I., Haslett C., Chilvers E.R. Regulation of neutrophil apoptosis by tumor necrosis factor-alpha: requirement for TNFR55 and TNFR75 for induction of apoptosis in vitro. Blood 1997, 90:2772-2783.
20. Lin Y.Z., Yao S.Y., Veach R.A., Torgerson T.R., Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J. Biol. Chem. 1995, 270:14255-14258.
21. Wei L., Alhenc-Gelas F., Soubrier F., Michaud A., Corvol P., Clauser E. Expression and characterization of recombinant human angiotensin I-converting enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes. J. Biol. Chem. 1991, 266:5540-5546.
22. Amour A., Knight C.G., English W.R., Webster A., Slocombe P.M., Knauper V., Docherty A.J., Becherer J.D., Blobel C.P., Murphy G. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett. 2002, 524:154-158.
23. Garton K.J., Gough P.J., Philalay J., Wille P.T., Blobel C.P., Whitehead R.H., Dempsey P.J., Raines E.W. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J. Biol. Chem. 2003, 278:37459-37464.
24. Yabkowitz R., Meyer S., Yanagihara D., Brankow D., Staley T., Elliott G., Hu S., Ratzkin B. Regulation of tie receptor expression on human endothelial cells by protein kinase C-mediated release of soluble tie. Blood 1997, 90:706-715.
25. Killar L., White J., Black R., Peschon J. Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE). Ann. NY Acad. Sci. 1999, 878:442-452.
26. Palsson-McDermott E.M., O'Neill L.A. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 2004, 113:153-162.
27. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., Georgopoulos S., Lesslauer W., Kollias G., Pfizenmaier K., et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80kDa tumor necrosis factor receptor. Cell 1995, 83:793-802.
28. Murphy G. Tissue inhibitors of metalloproteinases. Genom. Biol. 2011, 12:233.
29. Singh R.J., Mason J.C., Lidington E.A., Edwards D.R., Nuttall R.K., Khokha R., Knauper V., Murphy G., Gavrilovic J. Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc. Res. 2005, 67:39-49.
30. Nuttall R.K., Pennington C.J., Taplin J., Wheal A., Yong V.W., Forsyth P.A., Edwards D.R. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol. Cancer Res. 2003, 1:333-345.
31. Oppong S.Y., Hooper N.M. Characterization of a secretase activity which releases angiotensin-converting enzyme from the membrane. Biochem. J. 1993, 292(Pt 2):597-603.
32. Imaizumi T., Itaya H., Fujita K., Kudoh D., Kudoh S., Mori K., Fujimoto K., Matsumiya T., Yoshida H., Satoh K. Expression of tumor necrosis factor-alpha in cultured human endothelial cells stimulated with lipopolysaccharide or interleukin-1alpha. Arterioscler., Thromb., Vasc. Biol. 2000, 20:410-415.
33. Faustman D., Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nature Rev. Drug Discov. 2010, 9:482-493.
34. Weskamp G., Cai H., Brodie T.A., Higashyama S., Manova K., Ludwig T., Blobel C.P. Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. Mol. Cell Biol. 2002, 22:1537-1544.